Acumen Pharmaceuticals Stock EBITDA
| ABOS Stock | USD 2.37 0.06 2.60% |
Acumen Pharmaceuticals fundamentals help investors to digest information that contributes to Acumen Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Acumen Stock. The fundamental analysis module provides a way to measure Acumen Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acumen Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -51.6 M | -49 M |
Acumen | EBITDA |
Acumen Pharmaceuticals Company EBITDA Analysis
Acumen Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Acumen Pharmaceuticals EBITDA | (51.61 M) |
Most of Acumen Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acumen Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Acumen EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Acumen Pharmaceuticals is extremely important. It helps to project a fair market value of Acumen Stock properly, considering its historical fundamentals such as EBITDA. Since Acumen Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acumen Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acumen Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Acumen Ebitda
Ebitda |
|
According to the company disclosure, Acumen Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (51.61 Million). This is 105.88% lower than that of the Biotechnology sector and 151.53% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.32% higher than that of the company.
Acumen EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acumen Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acumen Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acumen Pharmaceuticals by comparing valuation metrics of similar companies.Acumen Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Acumen Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Acumen Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Acumen Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Acumen Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Acumen Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Acumen Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acumen Pharmaceuticals' value.| Shares | Laurion Capital Management Lp | 2024-09-30 | 867 K | Geode Capital Management, Llc | 2024-09-30 | 864.5 K | Hudson Bay Capital Management Lp | 2024-09-30 | 636 K | Pathstone Holdings Llc | 2024-06-30 | 480.2 K | State Street Corp | 2024-06-30 | 436.6 K | Jane Street Group Llc | 2024-06-30 | 427.7 K | Two Sigma Advisers, Llc | 2024-06-30 | 392.1 K | Two Sigma Investments Llc | 2024-09-30 | 309.5 K | Northern Trust Corp | 2024-09-30 | 308.9 K | Ra Capital Management, Llc | 2024-09-30 | 14.9 M | Franklin Resources Inc | 2024-09-30 | 3.5 M |
Acumen Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | (29.49 M) | ||||
| Shares Outstanding | 60.08 M | ||||
| Shares Owned By Insiders | 11.23 % | ||||
| Shares Owned By Institutions | 78.48 % | ||||
| Number Of Shares Shorted | 1.45 M | ||||
| Price To Book | 0.66 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | (32.36 M) | ||||
| EBITDA | (51.61 M) | ||||
| Net Income | (52.37 M) | ||||
| Cash And Equivalents | 189.91 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 28.49 M | ||||
| Current Ratio | 37.21 X | ||||
| Book Value Per Share | 3.62 X | ||||
| Cash Flow From Operations | (43.06 M) | ||||
| Short Ratio | 7.19 X | ||||
| Earnings Per Share | (1.38) X | ||||
| Price To Earnings To Growth | (0.23) X | ||||
| Target Price | 10.8 | ||||
| Number Of Employees | 51 | ||||
| Beta | 0.039 | ||||
| Market Capitalization | 142.39 M | ||||
| Total Asset | 310.12 M | ||||
| Retained Earnings | (222.8 M) | ||||
| Working Capital | 233.64 M | ||||
| Net Asset | 310.12 M |
About Acumen Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acumen Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acumen Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acumen Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.